生物
外显子
腺癌
体细胞
肺癌
选择性拼接
克拉斯
癌症研究
RNA剪接
信使核糖核酸
种系突变
突变
基因
遗传学
分子生物学
癌基因
癌症
核糖核酸
医学
病理
细胞周期
作者
Eric A. Collisson , Barry S. Taylor, Levi Garraway, Chip Stewart, Eric S. Lander, Daniel DiCara, Robert C. Onofrio, Mara Rosenberg, Jill Mesirov, Scott L. Carter, Pei Lin, Angela N. Brooks, Jaegil Kim, Peter S. Hammerman, Steven E. Schumacher, Gad Getz, Elena Helman, Lee Lichtenstein, Kristian Cibulskis, David Heiman
出处
期刊:Nature
[Nature Portfolio]
日期:2014-07-08
卷期号:511 (7511): 543-550
被引量:5780
摘要
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI